Literature DB >> 16279253

Study conduct, monitoring and data management in a trinational trial: the OPTIMA model.

Tassos C Kyriakides1, Abdel Babiker, Joel Singer, Mirek Piaseczny, John Russo.   

Abstract

The OPTions In Management with Antiretrovirals (OPTIMA) Trial, a collaboration between three governmental agencies in the USA, UK and Canada is a large-scale, multicenter, randomized controlled trial designed to compare the relative efficacy of different therapeutic strategies in HIV disease. The collaboration of three coordinating centers introduced unique data management issues including: a) use of different data systems for managing "country" trial data; b) two-way data transfer between the coordinating centers and the center where OPTIMA data is merged and analysis files are generated; and c) translation of certain data forms (mainly patient completed questionnaires) into French and Spanish. The involvement of three data centers provided a challenge in planning, designing and executing data management procedures in OPTIMA. Processes were implemented to ensure the trial's successful execution at the trinational level, without disregarding country-specific requirements and regulations. The OPTIMA model required a significant time and resource investment on behalf of all agencies involved, but allowed for autonomy and a sense of joint ownership of data in different countries.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16279253     DOI: 10.1191/1740774504cn022oa

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  4 in total

1.  A joint model for recurrent events and a semi-competing risk in the presence of multi-level clustering.

Authors:  Tae Hyun Jung; Peter Peduzzi; Heather Allore; Tassos C Kyriakides; Denise Esserman
Journal:  Stat Methods Med Res       Date:  2018-07-31       Impact factor: 3.021

2.  A joint frailty model provides for risk stratification of human immunodeficiency virus-infected patients based on unobserved heterogeneity.

Authors:  Tae Hyun Jung; Tassos Kyriakides; Mark Holodniy; Denise Esserman; Peter Peduzzi
Journal:  J Clin Epidemiol       Date:  2018-02-09       Impact factor: 6.437

3.  Designing and implementing sample and data collection for an international genetics study: the Type 1 Diabetes Genetics Consortium (T1DGC).

Authors:  Joan E Hilner; Letitia H Perdue; Elizabeth G Sides; June J Pierce; Ana M Wägner; Alan Aldrich; Amanda Loth; Lotte Albret; Lynne E Wagenknecht; Concepcion Nierras; Beena Akolkar
Journal:  Clin Trials       Date:  2010-07-05       Impact factor: 2.486

4.  Quality control of phenotypic forms data in the Type 1 Diabetes Genetics Consortium.

Authors:  Letitia H Perdue; Lotte Albret; Alan Aldrich; Amanda Loth; Elizabeth G Sides; Angela Dove; Ana M Wägner; Rebecca Waterman; June J Pierce; Beena Akolkar; Michael W Steffes; Joan E Hilner
Journal:  Clin Trials       Date:  2010-07-05       Impact factor: 2.486

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.